LENZ Therapeutics, Inc. financial data

Symbol
GRPH on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
445 Marine View Ave Suite 320, Del Mar, California
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Graphite Bio, Inc. (to 3/19/2024)
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.24 K % -43.7%
Debt-to-equity 30.7 % +96%
Return On Equity -96.4 % -62.9%
Return On Assets -61.2 % -130%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 25.5 M shares -56.1%
Common Stock, Shares, Outstanding 25.5 M shares -56.2%
Entity Public Float 151 M USD +0.47%
Common Stock, Value, Issued 0 USD -100%
Weighted Average Number of Shares Outstanding, Basic 4.72 M shares +142%
Weighted Average Number of Shares Outstanding, Diluted 4.72 M shares +142%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 32.3 M USD -50.1%
General and Administrative Expense 41 M USD +24.7%
Operating Income (Loss) -139 M USD -50.2%
Nonoperating Income (Expense) 10 M USD +128%
Net Income (Loss) Attributable to Parent -129 M USD -46.4%
Earnings Per Share, Basic 0.78 USD/shares +45.7%
Earnings Per Share, Diluted 0.78 USD/shares +45.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 200 M USD +187%
Cash, Cash Equivalents, and Short-term Investments 213 M USD +80764762%
Assets, Current 217 M USD -19.8%
Property, Plant and Equipment, Net 49 K USD -99.9%
Operating Lease, Right-of-Use Asset 578 K USD -85.6%
Other Assets, Noncurrent 0 USD -100%
Assets 217 M USD -29.9%
Accounts Payable, Current 7.13 M USD +258%
Employee-related Liabilities, Current 816 K USD -37.9%
Accrued Liabilities, Current 11.8 M USD
Liabilities, Current 18.9 M USD +31.7%
Operating Lease, Liability, Noncurrent 156 K USD -89%
Other Liabilities, Noncurrent 111 K USD
Liabilities 19.2 M USD -43.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1 K USD +99.8%
Retained Earnings (Accumulated Deficit) -112 M USD +58%
Stockholders' Equity Attributable to Parent 198 M USD
Liabilities and Equity 217 M USD -29.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -23.9 M USD -87%
Net Cash Provided by (Used in) Financing Activities 171 M USD +106%
Net Cash Provided by (Used in) Investing Activities 18 M USD
Common Stock, Shares Authorized 300 M shares 0%
Common Stock, Shares, Issued 25.5 M shares -56.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 165 M USD +135%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 200 M USD +74.6%
Deferred Tax Assets, Valuation Allowance 67.6 M USD +77.4%
Deferred Tax Assets, Gross 67.7 M USD +72.3%
Operating Lease, Liability 296 K USD -93.5%
Depreciation 2.4 M USD 0%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -16.7 M USD -31.5%
Lessee, Operating Lease, Liability, to be Paid 319 K USD -93.4%
Property, Plant and Equipment, Gross 0 USD -100%
Operating Lease, Liability, Current 433 K USD -86.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 161 K USD -57.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 117 K USD -92%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 23 K USD -91.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 41 K USD
Deferred Tax Assets, Operating Loss Carryforwards 30.8 M USD +93.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10 M shares 0%
Unrecognized Tax Benefits 3.56 M USD +31.7%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.49 M USD
Operating Lease, Payments 1.75 M USD +32.5%
Additional Paid in Capital 310 M USD -42.9%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 5 K USD +66.7%
Deferred Tax Assets, Net of Valuation Allowance 73 USD -93.8%
Share-based Payment Arrangement, Expense 11.4 M USD +10.1%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%